United States-based Inovio Pharmaceuticals has dosed the first participant with PENNVAX-GP in a randomised clinical trial that will evaluate its ability to drive remission of HIV infection, it was reported yesterday.
This vaccine targets all major HIV strains and focuses on improving the capacity of the immune system to eliminate or provide life-long control of HIV. This trial is part of a USD6.95m grant from the NIH's National Institute of Allergy and Infectious Diseases (NIAID) to produce a therapy using the company's PENNVAX-GP.
This Phase 1/2 HIV trial is a randomized, double-blinded, placebo-controlled study. The trial is divided into two cohorts, with all vaccines delivered through the CELLECTRA device.
Inovio president and CEO, Joseph Kim, said, 'We have already demonstrated that PENNVAX-GP generated the highest overall levels of T cell and antibody immune response rates ever demonstrated by an HIV vaccine in healthy volunteers. Here, we are going after the Holy Grail of HIV treatment – investigating if our vaccine used alone or in combination with other therapies could bring true remission of HIV in patients. The key to this trial is that T cells generated by our vaccines target the body's HIV reservoirs where the infection 'hides' from antiretroviral therapy. Inovio has already shown (in an HPV therapeutics trial) that our immunotherapy can generate sustained T cell responses which are able to traffic to an immunosuppressive tissue environment and eliminate virus-expressing cells. We expect results from this breakthrough study in late 2019.'
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer